Background: Scarring alopecia may take several forms, one of which is Frontal Fibrosing Alopecia
(FFA), a clinical variation of lichen planopilaris (LPP). Scarring alopecia on the hairline is a
characteristic of this condition, which mostly affects women after menopause. Purpose: This research
set out to conduct a retrospective trial of FFA in Egypt with the intention of evaluating its many
components, including its clinical features and treatment results. Methods: Fifty female patients with
frontal fibrosing alopecia were included in the research between January 2021 and January 2023 from
the dermatology outpatient clinic of Benha University hospital. All individuals who took part in the
study provided their written informed permission. A local ethics committee at Benha Faculty of
Medicine reviewed the study and gave its approval for it to include human volunteers. Trichoscopic
evaluation of frontal fibrosing alopecia and dermatological evaluation of clinical status were also
performed on all patients. Outcomes of treatment and durations of six months to a year of follow-up
were recorded.Findings: Our research comprised a total of fifty female patients. Onset occurred at an
average age of 47±5.7 years. The typical time frame was 1.5±0.5 years. Additionally, characteristic
symptoms of concurrent lichen planus were noted in 21 individuals (22.6%), and 28 patients (30.1%)
had thyroid problems. Twelve patients (12.9%) had hypertension, while six patients (6.5%) had
diabetes. There were less of other goods. Conclusion: FFA signifies a multi-faceted skin condition
that necessitates more research because to the lack of a definitive therapy. For FFA management, it
seems that intralesional corticosteroids, fenastride, and minoxidil 5% could work. Nevertheless, it is
important to evaluate these findings with the design restriction in mind.